(Q38478418)

English

A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression.

scientific article published on January 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21199704%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21199704%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21199704%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

P B Keiser

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21199704%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

S Biggs-Cicatelli

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21199704%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

E E Moran

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21199704%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

D H Schmiel

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21199704%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

V B Pinto

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21199704%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

R E Burden

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21199704%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

L B Miller

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21199704%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

R A Bowden

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21199704%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

J F Cummings

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21199704%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

W D Zollinger

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21199704%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

language of work or name

0 references

publication date

1 January 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21199704%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

number of pages

8

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21199704%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

29

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21199704%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21199704%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1413-1420

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21199704%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.039

7 January 2021

Meningococcal protein antigens and vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.039

7 January 2021

Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.039

7 January 2021

Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.039

7 January 2021

A universal vaccine for serogroup B meningococcus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.039

7 January 2021

Review of meningococcal group B vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.039

7 January 2021

A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.039

7 January 2021

Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.039

7 January 2021

Evaluation of a whole-blood cytokine release assay for use in measuring endotoxin activity of group B Neisseria meningitidis vaccines made from lipid A acylation mutants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.039

7 January 2021

Lipo-oligosaccharide immunotyping of Neisseria meningitidis by a whole-cell ELISA with monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.039

7 January 2021

Characterization of an antibody depletion assay for analysis of bactericidal antibody specificity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.039

7 January 2021

A general approach to standardization of the solid-phase radioimmunoassay for quantitation of class-specific antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.039

7 January 2021

Plasma fibrinogen levels after vaccination with a native outer membrane vesicle vaccine for Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.039

7 January 2021

Whole cell vaccination for meningococcus: Lessons from an idea whose time has gone

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.039

7 January 2021

Vaccine potential of the Neisseria meningitidis 2086 lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.039

7 January 2021

The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.039

7 January 2021

Immunization with recombinant Opc outer membrane protein from Neisseria meningitidis: influence of sequence variation and levels of expression on the bactericidal immune response against meningococci

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.039

7 January 2021

Biological activities of antibodies elicited by lipooligosaccharide based-conjugate vaccines of nontypeable Haemophilus influenzae in an otitis media model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.039

7 January 2021

Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.039

7 January 2021

Development of an anti-core lipopolysaccharide vaccine for the prevention and treatment of sepsis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.039

7 January 2021

Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.039

7 January 2021

Phase I study of a lipooligosaccharide-based conjugate vaccine against nontypeable Haemophilus influenzae.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.039

7 January 2021

Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.039

7 January 2021

Enhancement of T-helper type I immune responses against hepatitis B surface antigen by LPS derivatives adjuvanted liposomes delivery system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.039

7 January 2021

Differential activation of human and mouse Toll-like receptor 4 by the adjuvant candidate LpxL1 of Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.039

7 January 2021

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38478418&oldid=1775338588"